Cleerly and Allelica launch a new tool for assessing genetic risk in heart patients
The new test is designed to be used on its own or in tandem with Cleerly’s AI-powered CCTA evaluations.
The new test is designed to be used on its own or in tandem with Cleerly’s AI-powered CCTA evaluations.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
